Mineralocorticoid Receptor

Choose Selective Mineralocorticoid Receptor Inhibitors

Mineralocorticoid Receptor Products

  • All (4)
  • Mineralocorticoid Receptor Inhibitor (1)
  • Mineralocorticoid Receptor Antagonists (3)
  • New Mineralocorticoid Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
E0704New Esaxerenone (CS-3150)
S1707 Eplerenone (CGP 30083) Eplerenone (CGP 30083, SC-66110) is a mineralocorticoid receptor antagonist, and blocks the action of aldosterone, used to control high blood pressure.
Oncol Rep, 2021, 46(3)202
BMJ Open Diabetes Res Care, 2020,
Int J Mol Sci, 2019, 20(4)
S5273 Canrenone Canrenone (Aldadiene, SC-9376, RP-11614, 6,7-Dehydro-7α-desthioacetylspironolactone), a cardiovascular drug, a sort of steroid, is spironolactone's major metabolite and has been widely used as a nonselective aldosterone receptor antagonist clinically to treat heart failure, high blood pressure, edema, liver ascites, and other cardiovascular diseases.
S9702 Finerenone Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
E0704New Esaxerenone (CS-3150)
S1707 Eplerenone (CGP 30083) Eplerenone (CGP 30083, SC-66110) is a mineralocorticoid receptor antagonist, and blocks the action of aldosterone, used to control high blood pressure.
Oncol Rep, 2021, 46(3)202
BMJ Open Diabetes Res Care, 2020,
Int J Mol Sci, 2019, 20(4)
S5273 Canrenone Canrenone (Aldadiene, SC-9376, RP-11614, 6,7-Dehydro-7α-desthioacetylspironolactone), a cardiovascular drug, a sort of steroid, is spironolactone's major metabolite and has been widely used as a nonselective aldosterone receptor antagonist clinically to treat heart failure, high blood pressure, edema, liver ascites, and other cardiovascular diseases.
S9702 Finerenone Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
E0704New Esaxerenone (CS-3150)